M&A / Deals NewLimit’s $435M megaround; Lilly’s busy dealmaking week BioPharma DiveThe anti-aging biotech has secured one of the year s biggest venture fundings to bring its first drug into testing.Read full story pharminent June 3, 2026 (Last updated: June 4, 2026) BioPharma Dive The anti-aging biotech has secured one of the year s biggest venture fundings to bring its first drug into testing. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Travere beefs up rare kidney disease portfolio with up to $1.1B China dealNext: Legend surges on early data for ‘in vivo’ lymphoma cell therapy Related Stories M&A / Deals Spero snaps up Innovent immunology drug in strategic pivot pharminent July 14, 2026 M&A / Deals AstraZeneca takes another China trip, picking Dizal’s lung cancer drug for up to $1.5B pharminent July 14, 2026 M&A / Deals Novartis and Chai Discovery collaborate on antibody identification pharminent July 14, 2026
